These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 30926380)

  • 21. Repeat botulinum toxin-A injections for treatment of adult detrusor overactivity.
    Dowson C; Khan MS; Dasgupta P; Sahai A
    Nat Rev Urol; 2010 Dec; 7(12):661-7. PubMed ID: 21139642
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Botulinum toxin type A injection for neurogenic detrusor overactivity: clinical outcome in Japanese patients.
    Hikita K; Honda M; Kawamoto B; Panagiota T; Inoue S; Hinata N; Muraoka K; Takenaka A
    Int J Urol; 2013 Jan; 20(1):94-9. PubMed ID: 23126535
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Botulinum toxin type A for neurogenic detrusor overactivity due to spinal cord lesions in children: a retrospective study of seven cases.
    Do Ngoc Thanh C; Audry G; Forin V
    J Pediatr Urol; 2009 Dec; 5(6):430-6. PubMed ID: 19577520
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost comparison of intra-detrusor injection of botulinum toxin versus augmentation cystoplasty for refractory neurogenic detrusor overactivity in children.
    Kim SJ; Nang Q; RoyChoudhury A; Kern A; Sheth K; Jacobs M; Poppas D; Akhavan A
    J Pediatr Urol; 2022 Jun; 18(3):321-322. PubMed ID: 35305930
    [No Abstract]   [Full Text] [Related]  

  • 25. Factors that influence the urodynamic results of botulinum toxin in the treatment of neurogenic hyperactivity.
    Gutiérrez-Martín P; Vírseda-Chamorro M; Salinas Casado J; Gómez-Rodríguez A; Esteban-Fuertes M
    Actas Urol Esp; 2015 May; 39(4):217-21. PubMed ID: 25582926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and Urodynamic Results of Repeated Intradetrusor Onabotulinum Toxin A Injections in Refractory Neurogenic Detrusor Overactivity: Up to 5 Injections in a Cohort of Children With Myelodysplasia.
    Sekerci CA; Tanidir Y; Garayev A; Akbal C; Tarcan T; Simsek F
    Urology; 2018 Jan; 111():168-175. PubMed ID: 28943369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comment on: "Cost comparison of intra-detrusor injection of botulinum toxin versus augmentation cystoplasty for refractory Neurogenic Detrusor Overactivity in Children".
    Olsen LH; Djurhuus JC
    J Pediatr Urol; 2022 Jun; 18(3):323-324. PubMed ID: 35370093
    [No Abstract]   [Full Text] [Related]  

  • 28. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder.
    Haferkamp A; Schurch B; Reitz A; Krengel U; Grosse J; Kramer G; Schumacher S; Bastian PJ; Büttner R; Müller SC; Stöhrer M
    Eur Urol; 2004 Dec; 46(6):784-91. PubMed ID: 15548448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New therapeutic options for refractory neurogenic detrusor overactivity.
    Giannantoni A; Mearini E; Di Stasi SM; Costantini E; Zucchi A; Mearini L; Fornetti P; Del Zingaro M; Navarra P; Porena M
    Minerva Urol Nefrol; 2004 Mar; 56(1):79-87. PubMed ID: 15195033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preoperative urodynamic factors predicting outcome of botulinum toxin-A intradetrusor injection in children with neurogenic detrusor overactivity.
    Kim SW; Choi JH; Lee YS; Han SW; Im YJ
    Urology; 2014 Dec; 84(6):1480-4. PubMed ID: 25432842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intradetrusor Injections of Botulinum Toxin Type A in Children With Spina Bifida: A Multicenter Study.
    Hascoet J; Peyronnet B; Forin V; Baron M; Capon G; Prudhomme T; Allenet C; Tournier S; Maurin C; Cornu JN; Bouali O; Peycelon M; Arnaud A; Renaux-Petel M; Liard A; Karsenty G; Manunta A; Game X
    Urology; 2018 Jun; 116():161-167. PubMed ID: 29522865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence.
    Grosse J; Kramer G; Stöhrer M
    Eur Urol; 2005 May; 47(5):653-9. PubMed ID: 15826758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Refractory neurogenic detrusor overactivity.
    Cruz F; Silva C
    Int J Clin Pract Suppl; 2006 Dec; (151):22-6. PubMed ID: 17169007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surgical management of functional bladder outlet obstruction in adults with neurogenic bladder dysfunction.
    Utomo E; Groen J; Blok BF
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD004927. PubMed ID: 24859260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How to assess and predict success or failure of intra-detrusor injections with onabotulinumtoxinA.
    Przydacz M; Golabek T; Chlosta P
    Adv Clin Exp Med; 2019 Apr; 28(4):555-567. PubMed ID: 30729759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intradetrusor injections of onabotulinum toxin A (Botox®) 300 U or 200 U versus abobotulinum toxin A (Dysport®) 750 U in the management of neurogenic detrusor overactivity: A case control study.
    Peyronnet B; Castel-Lacanal E; Roumiguie M; Even L; Marque P; Soulié M; Rischmann P; Game X
    Neurourol Urodyn; 2017 Mar; 36(3):734-739. PubMed ID: 27037973
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Definition of botulinum toxin failure in neurogenic detrusor overactivity: Preliminary results of the DETOX survey].
    Peyronnet B; Sanson S; Amarenco G; Castel-Lacanal E; Chartier-Kastler E; Charvier K; Damphousse M; Denys P; de Seze M; Egon G; Even A; Forin V; Karsenty G; Kerdraon J; le Normand L; Loche CM; Manunta A; Mouracade P; Phe V; Previnaire JG; Ruffion A; Saussine C; Schurch B; Game X;
    Prog Urol; 2015 Dec; 25(17):1219-24. PubMed ID: 26318394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do repeat intradetrusor botulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity.
    Reitz A; Denys P; Fermanian C; Schurch B; Comperat E; Chartier-Kastler E
    Eur Urol; 2007 Dec; 52(6):1729-35. PubMed ID: 17884281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
    Giannantoni A; Mearini E; Del Zingaro M; Porena M
    Eur Urol; 2009 Mar; 55(3):705-11. PubMed ID: 18814955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity.
    Reitz A; Stöhrer M; Kramer G; Del Popolo G; Chartier-Kastler E; Pannek J; Burgdörfer H; Göcking K; Madersbacher H; Schumacher S; Richter R; von Tobel J; Schurch B
    Eur Urol; 2004 Apr; 45(4):510-5. PubMed ID: 15041117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.